// App-Quantinova.ai

4526 : Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.

Researchers

Presenter

  • Noah M. Hahn

Principal Investigators

  • Ashley Ross

  • George J. Netto

  • Jong Chul Park

  • Timothy A. Masterson

  • Michael O. Koch

  • Richard Bihrle

  • Richard Foster

  • Thomas A. Gardner

  • Liang Cheng

  • David R Jones

  • Kyle McElyea

  • George Sandusky

  • Ziyue Liu

  • Scott A Turner

  • Gregory J. Tsongalis

  • Elizabeth R. Plimack

  • Richard E. Greenberg

  • Daniel M. Geynisman

Medical Centers

  • Johns Hopkins Kimmel Cancer Center, Baltimore, MD

  • The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • The Johns Hopkins Medical Institutions, Baltimore, MD

  • Indiana University School of Medicine, Indianapolis, IN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Division of Biostatistics, Indiana University, Indianapolis, IN

  • Dartmouth Giesel School of Medicine, Lebanon, NH

  • The Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Fibroblast growth factor receptor 3

Drug/Treatment

  • Dovitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01732107

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved